Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies Nov 8, 2024 07:00AM
Kiora Pharmaceuticals (KPRX) Receives Investigational New Drug Approval to Initiate ABACUS-2 Oct 29, 2024 06:47AM
Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa Oct 29, 2024 06:45AM
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences Sep 25, 2024 09:55AM
Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies Aug 9, 2024 07:00AM
View Older Stories

Aug 6, 2024 07:03AM Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences
Jul 30, 2024 06:48AM Kiora Pharmaceuticals (KPRX) Granted EU Orphan Medicinal Product Designation for KIO-301
Jul 30, 2024 06:45AM Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies
Jul 10, 2024 07:00AM Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation
Jul 1, 2024 06:57AM Kiora Pharmaceuticals (KPRX) Appoints Lisa Walters-Hoffert to its Board
Jul 1, 2024 06:54AM Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors
Jun 25, 2024 06:45AM Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board
May 29, 2024 06:44PM Lytham Partners Spring 2024 Investor Conference Starts Tomorrow, May 30, 2024
May 20, 2024 07:00AM Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences
May 10, 2024 07:00AM Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease
May 8, 2024 07:00AM Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference
May 6, 2024 07:03AM Kiora Pharmaceuticals (KPRX) Reports Additional Clinical Data for KIO-301
May 6, 2024 07:00AM Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa
Apr 11, 2024 07:04AM Kiora Pharmaceuticals (KPRX) Receives Grant from Choroideremia Research Foundation
Apr 11, 2024 07:00AM Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Stud
Apr 5, 2024 07:00AM Kiora Pharmaceuticals to Present at Upcoming Investor Conferences
Mar 28, 2024 06:45AM Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
Mar 25, 2024 07:00AM Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases
Mar 8, 2024 07:02AM Kiora Pharmaceuticals (KPRX) Announces Publication of Phase 1 Study
Mar 8, 2024 07:00AM Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye
Feb 1, 2024 05:49AM Kiora Pharmaceuticals (KPRX) Announces $45M Private Placement
Jan 31, 2024 06:40PM Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
Jan 31, 2024 05:17PM Kiora Pharmaceuticals (KPRX) and Thea Open Innovation Enter Agreement to Develop and Commercialize KIO-301
Jan 31, 2024 05:15PM Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million i
Nov 9, 2023 07:18AM Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa
Nov 4, 2023 12:15PM AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa
Oct 16, 2023 07:00AM Kiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor Conference
Oct 3, 2023 07:02AM Kiora Pharmaceuticals (KPRX) Granted NDA Approval to Expand Phase 1b Study of KIO-301
Oct 3, 2023 07:00AM Kiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Pat
Sep 21, 2023 07:02AM Kiora Pharmaceuticals (KPRX) Announces Chairman Retirement
Sep 21, 2023 07:00AM Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years
Sep 18, 2023 07:00AM Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa
Sep 14, 2023 07:03AM Kiora Pharmaceuticals (KPRX) to Present Topline Results from the ABACUS Study
Sep 14, 2023 07:01AM Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosa
Sep 1, 2023 07:00AM Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27
Aug 29, 2023 01:43PM Kiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal Diseases
Aug 23, 2023 07:02AM Kiora Pharmaceuticals (KPRX) Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds
Aug 23, 2023 07:00AM Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitis
Aug 22, 2023 01:06PM Kiora Pharmaceuticals Taps B2i Digital to Deploy Data-Driven Investor Awareness Program
Aug 16, 2023 07:00AM Kiora Pharmaceuticals Webcasts Its Investor Presentation from the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
Aug 8, 2023 07:00AM Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress
Aug 3, 2023 07:00AM Kiora Pharmaceuticals, Inc. and Choroideremia Research Foundation Partner to Advance Novel Choroideremia Treatment
Aug 1, 2023 07:03AM Kiora Pharmaceuticals (KPRX) Appoints Carmine Stengone to its Board
Aug 1, 2023 07:00AM Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors
Jul 5, 2023 07:04AM Kiora Pharmaceuticals (KPRX) Receives $1.2M in Research Tax Credits
Jul 5, 2023 07:00AM Kiora Pharmaceuticals Receives $1.2 Million in Research Tax Credits to Advance the Treatment of Ophthalmic Disease
Jun 15, 2023 07:02AM Kiora Pharmaceuticals (KPRX) and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
Jun 15, 2023 07:00AM Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
Jun 14, 2023 08:00AM Kiora Pharmaceuticals to Present at Upcoming Investor Conferences
Jun 6, 2023 04:30PM Kiora Pharmaceuticals Announces Closing of $6.3 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
View Older Stories